NCT05697198View on ClinicalTrials.gov

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

CompletedOBSERVATIONAL
Enrollment

1,429

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Lung CancerOvarian CancerUterine CancerColorectal CancerStomach CancerEsophageal CancerPancreatic CancerMelanomaBreast CancerHead and Neck CancerSoft Tissue SarcomaRhabdomyosarcomaProstate Cancer
Interventions
DIAGNOSTIC_TEST

OmniSeq Test

Genomic and immune profiling assay for all solid tumors

Trial Locations (8)

28078

Clinical Site, Huntersville

29732

Clinical Site, Rock Hill

31021

Clinical Site, Dublin

32763

Clinical Site, Orange City

34994

Clinical Site, Stuart

35958

Clinical Site, Fort Payne

46804

Clinical Site, Fort Wayne

70433

Clinical Site, Covington

All Listed Sponsors
lead

Labcorp Corporation of America Holdings, Inc

INDUSTRY